通过整合白血病诊疗与单倍体供者改善非 favorable 风险急性白血病及骨髓增生异常综合征患者接受造血干细胞移植的可及性并减少种族差异
研究纳入2016至2021年在本中心接受初始治疗的256例<75岁非favorable风险急性白血病/骨髓增生异常综合征患者,147例(57%)接受了计划性造血干细胞移植(HCT),<60岁患者中为70%。logistic回归显示年龄(每增加10岁OR 1.50;P<.001)和种族(黑人vs白人OR 2.05;P=.023)是未接受HCT的显著因素。中位至HCT时间118天,黑人与白人相似;里程碑分析显示初始治疗后6个月内HCT生存更优,多变量分析显示HCT带来显著生存获益(HR 0.60;P=.020)。
要点
- 256例非favorable风险急性白血病/骨髓增生异常综合征患者中147例(57%)接受了计划性HCT,<60岁患者中为70%。
- 年龄(每增加10岁OR 1.50;P<.001)和黑人种族(vs白人OR 2.05;P=.023)与未接受HCT显著相关。
- 多变量分析显示HCT带来显著生存获益(HR 0.60;P=.020),初始治疗后6个月内HCT生存更优。
核心结论
- 通过整合HCT/白血病诊疗和使用单倍体供者,当前大多数<75岁患者可获得计划性HCT,但黑人患者未接受HCT的风险仍较高。
- 多变量分析显示HCT带来显著生存获益(HR 0.60;P=.020)。
研究设计与样本
- 研究纳入2016至2021年在本中心接受初始治疗的256例<75岁非favorable风险急性白血病/骨髓增生异常综合征连续患者。
主要发现
- 147例(57%)接受了计划性HCT,<60岁患者中为70%。
- logistic回归显示年龄(每增加10岁OR 1.50;P<.001)和种族(黑人vs白人OR 2.05;P=.023)是未接受HCT的显著因素。
- 未接受HCT的原因包括合并症(37%)、KPS差、缺乏照护者支持、难治性恶性肿瘤(各19%)和患者拒绝(17%),缺乏供者或保险罕见(各3%)。
- 在≥60岁患者中,合并症(49% vs 15%;P<.001)和KPS差(25% vs 10%;P=.06)更常见,缺乏照护者较少见(13% vs 30%;P=.031)。
- 黑人vs白人患者中缺乏照护者更常见(37% vs 11%;P=.002);初始治疗至HCT的中位时间为118天,黑人与白人相似。
关键数值与推荐
- 年龄每增加10岁未接受HCT的OR为1.50(P<.001)。
- 黑人vs白人未接受HCT的OR为2.05(P=.023)。
- HCT的生存获益HR为0.60(P=.020)。
- ≥60岁患者合并症49% vs 15%(P<.001),KPS差25% vs 10%(P=.06),缺乏照护者13% vs 30%(P=.031)。
- 黑人vs白人缺乏照护者37% vs 11%(P=.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Few patients with nonfavorable risk (NFR) acute leukemia and myeloid dysplasia syndrome (AL/MDS) undergo allogeneic transplantation (HCT). We assessed whether this could be improved by integrating HCT/leukemia care and the use of haploidentical donors. Of 256 consecutive patients aged <75 years who received initial therapy at our center for NFR AL/MDS from 2016 to 2021, 147 (57%) underwent planned HCT (70% for patients aged <60 years). In the logistic regression analysis, age (OR 1.50 per 10-year increment; P < .001) and race (Black vs White [OR 2.05; P = .023]) were significant factors for failure to receive HCT. Reasons for no HCT included comorbidities (37%), poor KPS, lack of caregiver support, refractory malignancy (19% each), and patient refusal (17%). Lack of donor or insurance were rarely cited (3% each). In older patients (≥60 years), comorbidities (49 vs 15%; P < .001) and KPS (25% vs 10%; P = .06) were more common, and lack of caregivers was less common (13% vs 30%; P = .031). In Black vs White patients, lack of caregivers (37% vs 11%; P = .002) was more frequent. The median time from initial treatment to HCT was 118 days and was similar for Black and White patients. Landmark analysis showed that HCT within 6 months of the initial treatment produced better survival. Multivariable analysis showed that HCT resulted in a significant survival benefit (HR 0.60; P = .020). With the above approach, most of the currently treated patients aged <75 years can access planned HCT. Black patients remain at greater risk of not receiving HCT.
引用
- Bashey A, Zhang X, Morris LE, et al. Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors. Blood Adv. 2023. PMID: 36961350. doi:10.1182/bloodadvances.2023009765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。